Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Acquires 20,000 Shares of Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Ingmar Bruns bought 20,000 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was bought at an average price of $2.28 per share, with a total value of $45,600.00. Following the completion of the acquisition, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This trade represents a 120.27 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $2.43 on Friday. The firm’s 50 day moving average is $2.65 and its 200-day moving average is $3.12. Zentalis Pharmaceuticals, Inc. has a 52-week low of $1.61 and a 52-week high of $18.07. The firm has a market capitalization of $173.16 million, a P/E ratio of -0.98 and a beta of 1.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36. Equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC boosted its holdings in Zentalis Pharmaceuticals by 18.5% in the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after purchasing an additional 11,748 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after buying an additional 353,384 shares during the last quarter. Verition Fund Management LLC grew its position in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after buying an additional 951,500 shares in the last quarter. Primecap Management Co. CA increased its stake in shares of Zentalis Pharmaceuticals by 21.6% in the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after buying an additional 265,690 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Zentalis Pharmaceuticals by 115.6% in the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock valued at $171,000 after acquiring an additional 30,240 shares in the last quarter.

Analyst Ratings Changes

Several brokerages have recently issued reports on ZNTL. HC Wainwright lowered their price objective on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Wedbush restated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Guggenheim reduced their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Wells Fargo & Company dropped their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Finally, UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.